Nantahala Capital Management’s Dyne Therapeutics DYN Stock Holding History

Nantahala Capital Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-702,884	Closed	-$8.89M	–	161
2025 Q3	$8.89M	Sell	702,884 -42,178	-6%	-$481K	0.31%	74
2025 Q2	$7.09M	Buy	745,062 +400,000	+116%	+$4.4M	0.28%	70
2025 Q1	$3.61M	Buy	+345,062	New	+$4.94M	0.14%	88
2024 Q2	–	Sell	-435,256	Closed	-$12.4M	–	136
2024 Q1	$12.4M	Sell	435,256 -207,533	-32%	-$4.69M	0.71%	30
2023 Q4	$8.55M	Sell	642,789 -40,375	-6%	-$394K	0.51%	45
2023 Q3	$6.12M	Buy	683,164 +90,000	+15%	+$969K	0.52%	43
2023 Q2	$6.67M	Buy	593,164 +414,263	+232%	+$4.89M	0.65%	39
2023 Q1	$2.06M	Buy	+178,901	New	+$2.32M	0.16%	74

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Nantahala Capital Management's DYN Position: Q4 2025 in Review

Nantahala Capital Management sold out of Dyne Therapeutics (DYN) in Q4 2025, closing a stake of 702,884 shares — an estimated $8.89M sold.

Nantahala Capital Management first reported a position in DYN in Q1 2023 and held it in 8 quarters. The position peaked at $12.4M in Q1 2024. 232 funds tracked by Wall St. Rank hold DYN as of Q4 2025.

Nantahala Capital Management reported no remaining Dyne Therapeutics position as of Q4 2025 after selling out during the quarter.
Nantahala Capital Management sold 702,884 Dyne Therapeutics shares in Q4 2025, an estimated $8.89M.
Nantahala Capital Management first reported a position in Dyne Therapeutics in Q1 2023 and held it in 8 quarters.
Nantahala Capital Management's Dyne Therapeutics position peaked at $12.4M in Q1 2024.
232 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2025.

Based on Nantahala Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.